Quince Therapeutics, Inc. (QNCX)
NASDAQ: QNCX · IEX Real-Time Price · USD
0.740
-0.010 (-1.36%)
Jul 22, 2024, 10:05 AM EDT - Market open
Quince Therapeutics Employees
Quince Therapeutics had 32 employees as of December 31, 2023. The number of employees increased by 11 or 52.38% compared to the previous year.
Employees
32
Change (1Y)
11
Growth (1Y)
52.38%
Revenue / Employee
n/a
Profits / Employee
-$946,250
Market Cap
31.83M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Cutera | 430 |
Orgenesis | 146 |
IRIDEX | 111 |
ReWalk Robotics | 108 |
ImmuCell | 79 |
Immuneering | 68 |
Longeveron | 24 |
Reviva Pharmaceuticals Holdings | 15 |
QNCX News
- 27 days ago - Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia - Business Wire
- 7 weeks ago - Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System - Business Wire
- 2 months ago - Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results - Business Wire
- 2 months ago - Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference - Business Wire
- 4 months ago - Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results - Business Wire
- 5 months ago - Quince Therapeutics Launches Scientific Advisory Board - Business Wire
- 5 months ago - Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors - Business Wire
- 5 months ago - Quince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference - Business Wire